When people are affected by diseases, they deserve the best possible treatment. Thanks to the development of innovative medicines, it is possible to achieve increasingly better treatment outcomes for them. With the discovery, development and delivery of biologics, we serve patients in the fields of oncology, hematology, cardiovascular disease, bone diseases and (rare) inflammatory diseases.
Oncology & Hematology
- Particular types of cancer, such as colorectal cancer and skin cancer
- Hematological cancers, which affect particular blood cells, such as acute lymphoblastic leukemia (ALL) and multiple myeloma (MM)
- Immune thrombocytopenia (ITP), a disease in which the immune system attacks the body’s own platelets
- Rare blood disorders, such as paroxysmal nocturnal hemoglobinuria (PNH)
- A shortage of white or red blood cells, for example after chemotherapy
Bone diseases
- Osteoporosis in post-menopausal women and also in men
- Bone loss caused by certain cancer treatments or the long-term use of glucocorticoids in patients at increased risk of fractures
- Bone complications caused by bone metastases, where cancer has spread to the bone, in patients with advanced cancer
Cardiovascular diseases
- Elevated LDL cholesterol (the ‘bad’ cholesterol) in patients with a very high risk of cardiovascular diseases
Kidney diseases
- Chronic kidney disease and related conditions, such as anaemia and secondary hyperparathyroidism
- Rare disorders that can affect the blood and kidneys, such as atypical haemolytic uraemic syndrome (aHUS)
(Rare) Inflammatory diseases
- Rheumatic diseases, such as rheumatoid arthritis and psoriatic arthritis
- Skin diseases, such as plaque psoriasis
- Inflammatory bowel disease (IBD), such as Crohn’s disease and ulcerative colitis
- Neuromyelitis optica spectrum disorder (NMOSD)
- Generalised myasthenia gravis (gMG)
Eye diseases
- Wet age-related macular degeneration (AMD)
- Macular oedema caused by diabetes or blockage of a retinal vein
Our medicines
Read more about which biologics and biosimilars we sell in the Netherlands and how they tackle diseases.
By selecting the Yes option, leaving Amgen.nl option you understand that you are leaving the corporate page of Amgen nl and that you will be redirected to another Internet site belonging to third parties, for whose content or opinions Amgen nl is not responsible and makes no representations regarding such content or its accuracy. By selecting this option and accessing linked third party sites, you understand that you do so at your own risk.
The website to which you will be redirected may be designed exclusively for residents of a particular country or countries, as advertised on that website. As a consequence, the website to which you will be directed may contain information on pharmaceutical products or indications that are not approved in nl. If You reside in a country other than the one to which such website is directed, please contact your local Amgen affiliate for the correct information on products in your country of residence.
By selecting the Yes option, leaving Amgen.nl option you understand that you are leaving the corporate page of Amgen nl and that you will be redirected to another Internet site belonging to third parties, for whose content or opinions Amgen nl is not responsible and makes no representations regarding such content or its accuracy. By selecting this option and accessing linked third party sites, you understand that you do so at your own risk.
The website to which you will be redirected may be designed exclusively for residents of a particular country or countries, as advertised on that website. As a consequence, the website to which you will be directed may contain information on pharmaceutical products or indications that are not approved in nl. If You reside in a country other than the one to which such website is directed, please contact your local Amgen affiliate for the correct information on products in your country of residence.